TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23743969
Drug: Red Bull
Normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Bull Energy Shot™ (RB; 80 mg caffeine)
Study: 23743969
Drug: Placebo (PLA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA; 0 mg caffeine)
Study: 10867984
Drug: mecamylamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: mecamylamine (20 mg PO)
Study: 6866592
Drug: Methylphenidate HCl
Normalized name: methylphenidate HCl
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate HCl (Ritalin) administered intravenously or orally with breakfast
Study: 6866592
Drug: Methylphenidate HCl
Normalized name: methylphenidate HCl
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate HCl (Ritalin) administered intravenously or orally in a fasted state
Study: 15849207
Drug: Pethidine 20
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 20 mg (Group P)
Study: 15816573
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg kg(‐1) (Group K)
Study: 12221161
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of highest voltage with narrowest pulse width
Study: 10458252
Drug: CJ‐11,974 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJ‐11,974 100 mg
Study: 7798528
Drug: Etilefrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etilefrine (10 mg three times a day)
Study: 2086821
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AZT and CMZ or PIPC for Escherichia coli infections
Study: 25884315
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) supplementation (1.2 g.kg(‐1) body mass.h(‐1) in a 20% CHO solution)
Study: 25884315
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) supplementation (6 mg.kg(‐1) body mass)
Study: 23665888
Drug: No preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preventive care (routine medical treatment)
Study: 21819189
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (coil placement)
Study: 21819189
Drug: Neurosurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurosurgical treatment (clip occlusion)
Study: 19135345
Drug: Oral vinpocetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinpocetine (VP) 30 mg for 3 months
Study: 15472176
Drug: GH at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH at 25.0 microg/kg x d (pediatric dose)
Study: 15472176
Drug: GH at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH at 12.5 microg/kg x d (adult dose)
Study: 10487666
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (both doses)
Study: 15472176
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no GH treatment)
Study: 11549829
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg twice daily), Amoxycillin (1000 mg twice daily), Clarithromycin (500 mg twice daily) for 14 days (LAC)
Study: 11549829
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg four times daily), Bismuth subsalicylate (2 tablets four times daily), Metronidazole (250 mg four times daily), Tetracycline (250 mg four times daily) for 14 days (LBMT)
Study: 8111257
Drug: Low total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low total fat diet (8% saturated fat, approximately 200 mg/day cholesterol)
Study: 8111257
Drug: High unsaturated
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High unsaturated fat diet (8% saturated fat, approximately 200 mg/day cholesterol)
Study: 2888424
Drug: Terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60 mg
Study: 2569997
Drug: Clemastine 1
Normalized name: clemastine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine 1 mg
Study: 26521106
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CYA) combined with low-dose corticosteroids (CS)
Study: 26521106
Drug: Cyclophosphamide (CPA)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CPA) combined with low-dose corticosteroids (CS)
Study: 12651203
Drug: favourable response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: favourable response to salvage therapy
Study: 12651203
Drug: no specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: no specific therapy
Study: 1576095
Drug: Low-dose nisoldipine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nisoldipine (2 micrograms/kg) as a single intravenous injection over a 3-minute period
Study: 1576095
Drug: High-dose nisoldipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nisoldipine (double the low dose)
Study: 24576886
Drug: PACK-CXL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACK-CXL treatment in addition to antimicrobial therapy
Study: 20349405
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (1.7 g for three months)
Study: 18751997
Drug: 2DW (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2DW (n = 25) - participated in 90‐min group training twice a week for 12 weeks
Study: 11413076
Drug: Lamifiban (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamifiban (an intravenous GP IIb/IIIa antagonist)
Study: 9786314
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) administered by prolonged infusion
Study: 9786314
Drug: New topoisomerase
Approvals — FDA: no, EMA: no, PMDA: no
Description: New topoisomerase I inhibitor irinotecan
Study: 28653108
Drug: Antioxidant-containing ointment
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant-containing ointment applied topically for 16 weeks, starting 3 days prior to chemotherapy.
Study: 28653108
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied topically for 16 weeks, starting 3 days prior to chemotherapy.
Study: 21569300
Drug: Problem solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem solving therapy, postcards, patient support, cultural assessment, improved access to primary care, risk management strategy
Study: 16531621
Drug: G‐CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (10 microg/kg of body weight) for 6 days
Study: 29633621
Drug: Ordinary hen
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary hen eggs (3 eggs daily, 277 mg omega-3 PUFAs/day for 3 weeks)
Study: 24390764
Drug: Fasudil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasudil (30 mg intravenously twice a day for 14 days)
Study: 21430703
Drug: 0.75% LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% LDE225 cream
Study: 18829872
Drug: Acute and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute and maintenance interpersonal and social rhythm therapy
Study: 11386413
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not treated with chemotherapy)
Study: 12763216
Drug: Temozolomide 200
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 200 mg/m(2)/day, administered orally for 5 consecutive days of a 28-day cycle, continued for up to six cycles.
Study: 11141365
Drug: Ibuprofen suspension
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen suspension (7 mg/kg)
Study: 11141365
Drug: Effervescent granules
Normalized name: Klorvess Effervescent Granules for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent granules (200 mg for 25-40 kg; 400 mg for 35-40 kg; 400 mg for >40 kg)
Study: 2841841
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g soy polysaccharide
Study: 3012991
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g soy polysaccharide
Study: 19954383
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp-SP) in HIV-negative mothers
Study: 19954383
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp-SP)
Study: 7105818
Drug: Cefaclor, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor, 150 mg 3-times daily
Study: 7105818
Drug: Amoxycillin, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin, 150 mg 3-times daily
Study: 24589242
Drug: Bromelain (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromelain (4 × 250 mg)
Study: 24589242
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (4 × 25 mg)
Study: 8349067
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg/d)
Study: 22070512
Drug: Ilaprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole (10 mg/d)
Study: 12200812
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of recombinant human EPO (rHuEPO) in groups A and C1
Study: 12200812
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of rHuEPO in groups B and C2
Study: 6182469
Drug: Starch-blocker tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch-blocker tablets
Study: 31646767
Drug: Single 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 10 mg/kg intravenous dose of methylprednisolone
Study: 31646767
Drug: Higher (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher (30 mg/kg) or more frequent (twice) dosing of methylprednisolone
Study: 1622175
Drug: Fleroxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (400 mg) administered orally and intravenously
Study: 29106448
Drug: LMWH enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH enoxaparin (1 mg/kg)
Study: 26216477
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g GAA/kg diet
Study: 26216477
Drug: 0.6 g
Normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g GAA/kg diet
Study: 26216477
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g GAA/kg diet
Study: 26216477
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g GAA/kg diet with 0 g ARG/kg diet
Study: 26216477
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g GAA/kg diet with 3 g ARG/kg diet
Study: 26216477
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g GAA/kg diet with 6 g ARG/kg diet
Study: 26216477
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g GAA/kg diet with 9 g ARG/kg diet
Study: 12970285
Drug: recombinant luteinizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant luteinizing hormone (r-LH) 1 mg (n = 13)
Study: 427002
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg i.v. pindolol
Study: 427002
Drug: Oral pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pindolol (5, 10, and 20 mg)
Study: 31655883
Drug: Local corticosteroid
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local corticosteroid injection (LCI)
Study: 30116006
Drug: 8-mg ondansetron
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-mg ondansetron
Study: 30116006
Drug: 16-mg ondansetron
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-mg ondansetron
Study: 30116006
Drug: 24-mg ondansetron
Normalized name: ondansetron 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-mg ondansetron
Study: 27471856
Drug: Neonatal vitamin
Normalized name: NEONATAL VITAMIN Tablet
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal vitamin A supplementation (single dose of 50,000 international units within 48-72 hours after birth)
Study: 25552328
Drug: 4:1 mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4:1 mixture of 9 mg/ml propofol and 2.25 mg/ml ketamine (Group 2)
Study: 25552328
Drug: 2:1 mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2:1 mixture of 9 mg/ml propofol and 4.5 mg/ml ketamine (Group 1)
Study: 19135574
Drug: Carra/LNG gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carra/LNG gel (0.75 mg in 4 mL) with sexual intercourse after 2-4 hours
Study: 19135574
Drug: Carra/LNG gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carra/LNG gel (0.75 mg in 4 mL) with abstinence
Study: 26224101
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of water
Study: 9211770
Drug: Iodixanol (Visipaque
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol (Visipaque 270 mg I/ml)
Study: 14616202
Drug: Iomeprol (Iomeron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol (Iomeron 300 mg I/ml)
Study: 21196806
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment
Study: 6969194
Drug: aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 600 mg t.d.s.
Study: 29800130
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of nitric oxide (iNO)
Study: 24517173
Drug: Personalized oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized oxycodone dosing based on CYP2D6 phenotype testing and clinical pharmacokinetics.
Study: 24517173
Drug: CYP2D6 phenotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2D6 phenotype testing and pharmacokinetics analysis.
Study: 8749696
Drug: Urinary beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary beta 2‐microglobulin excretion > 500 ng/min
Study: 8749696
Drug: Urinary beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary beta 2‐microglobulin excretion < or = 500 ng/min
Study: 30629458
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acid supplementation (5 g/d)
Study: 17114017
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) therapy
Study: 15478853
Drug: Endoscopic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapies
Study: 11874940
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg pioglitazone
Study: 9091801
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg orally every 12 hours for five days)
Study: 8371190
Drug: Topical APF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical APF gel (1.2% F‐) with daily use of placebo mouthrinse (Group B)
Study: 8371190
Drug: Fluoridated mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated mouthrinse daily, ACT (0.05% F‐) (Group C)
Study: 8371190
Drug: Placebo mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthrinse daily (Group A)
Study: 18339792
Drug: B-type natriuretic
Normalized name: B-type natriuretic peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-type natriuretic peptide (BNP) levels in patients requiring ICU treatment
Study: 15735109
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of iron (DI)
Study: 15735109
Drug: Weekly dose
Normalized name: XPOVIO 60 MG Weekly Dose Carton Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly dose of multiple micronutrients
Study: 12889590
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (metronidazole plus erythromycin)
Study: 1425054
Drug: Diosmin (Daflon);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmin (Daflon); 12 tablets in three divided doses for the first four days, then 2 tablets twice daily for another 10 days.
Study: 3936108
Drug: Clonidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (200 micrograms IV infusion)
Study: 28915286
Drug: IVM+BR (Ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVM+BR (Ivermectin 1% cream and Brimonidine 0.33% gel)
Study: 23663749
Drug: Advancing Recovery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advancing Recovery Framework (payer and treatment organization changes)
Study: 23663749
Drug: Treatment organization
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment organization changes alone
Study: 15656523
Drug: Routine group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine group (standard root canal therapy procedures)
Study: 15656523
Drug: Medicament group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicament group (dexamethasone tablets after instrumentation)
Study: 11134469
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) 300 mg twice daily from 36 weeks' gestation until labor, then every 3 hours until delivery
Study: 3116443
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azathioprine and OKT3
Study: 29910054
Drug: Optimal Medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Therapy (OMT) alone
Study: 31747093
Drug: Unpasteurised maternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unpasteurised maternal milk (MM) intake (mL/kg/d)
Study: 30739837
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) with weekly cisplatin regimen
Study: 16792559
Drug: 4-methylpyrazole (4-MP)
Normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-methylpyrazole (4-MP) treatment before ethanol consumption
Study: 16792559
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment before ethanol ingestion
Study: 28933336
Drug: Oxycodone once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone once-daily (OOD) 10 mg (oxycodone HCL 10-mg PR tablets XL)
Study: 28933336
Drug: Oxycodone twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxycodone twice-daily (OTD) 5 mg (oxygens 5-mg tablets)
Study: 9562231
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of cephalosporins and aminoglycosides
Study: 20799359
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (80 ppm)
Study: 7930234
Drug: Nitroprusside (maximally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside (maximally tolerated dose)
Study: 29386313
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle
Study: 23423269
Drug: Continuous corticosteroid
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous corticosteroid therapy (CCS)
Study: 17728331
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ETN + MTX)
Study: 17728331
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (previously receiving MTX or ETN monotherapy)
Study: 11726257
Drug: Moderate Load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate Load (ML) - 13-15 repetitions with a moderate load on the chest press exercise, n = 16
Study: 11726257
Drug: Medicine Ball
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine Ball (MB) - 13-15 medicine ball chest passes, n = 11
Study: 2821052
Drug: Naloxone (10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10-mg iv bolus dose followed by an infusion of 30 micrograms/kg . h)
Study: 23355361
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of ranolazine 500 mg twice daily for 7 days
Study: 9840848
Drug: Ropivacaine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine at 10 mL/hour
Study: 8030688
Drug: Sequential estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential estradiol and norethindrone acetate (Trisequens)
Study: 1176289
Drug: Kallikrein (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kallikrein (a kinin-liberating proteinase) administered parenterally and orally over a period of seven weeks.
Study: 1176289
Drug: Parenteral application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral application of kallikrein.
Study: 1176289
Drug: Kallikrein treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kallikrein treatment.
Study: 29790405
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education intervention during 6-month therapy